References:
1. Product Information: Nicolar(R), niacin. Rhone-Poulenc Rorer Pharmaceuticals, Fort Washington, PA; 1996.
2. Patterson DJ, Dew EW, Gyorkey F et al: Niacin hepatitis. South Med J 1983; 76(2):239-241.
3. Cohen L & Morgan J: Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol. J Fam Pract 1988; 26:145-150.
4. Taketomo CK, Hodding JH & Kraus DM: Pediatric Dosage Handbook, 5th ed. Lexicomp, Hudson, Ohio; 1998:783.
5. Darras BT, Ampola MG, Dietz WH et al: Intermittent dystonia in Hartnup disease. Pediatr Neurol 1989; 5:118-120.
6. Product Information: Lipitor(TM), atorvastatin. Parke-Davis, Morris Plains, NJ; 1996.
7. Product Information: Baycol(TM), cerivastatin sodium. Bayer Corporation, West Haven, CT; 1997.
8. Rockwell KA: Potential interaction between niacin and transdermal nicotine (letter). Ann Pharmacother 1993;27:1283-1284.
9. Patterson DJ, Dew EW, Gyorkey F et al: Niacin hepatitis. South Med J 1983; 76:240-241.
10. Crouse JR III: New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coronary Artery Disease 1996; 7:321-326.
11. Schwab RA & Bachhuber BH: Delirium and lactic acidosis caused by ethanol and niacin co-ingestion. Am J Emerg Med 1991; 9:363-365.
12. Figge HL, Figge J, Souney PF et al: Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 1988; 8:287-294.
13. Product Information: Niaspan(R), niacin, extended release tablet. Kos Pharmaceuticals, Miami, FL; 1997.
14. Donowitz M, Wicks J & Sharp GW: Drug therapy for diarrheal diseases: a look ahead. Rev Infect Dis 1986; 8(suppl 2): S18-S20.
15. O'Hara JO, Jolly PN, Nicol CG: The therapeutic efficacy of inositol nicotinate (Hexopal(R)) in intermittent claudication: a controlled trial. Br J Clin Pract 1988; 42(9): 377-383.
16. Jonas WB, Rapoza CP & Blair WF: The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 1996; 45(7): 330-334.
17. Pasternak RC, Brown LE, Stone PH et al: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized, placebo-controlled trial: Harvard Atherosclerosis Reversibility Project (HARP) study group. Ann Intern Med 1996; 125(7): 529-540.
18. Ding RW, Kolbe K, Merz B et al: Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 19889; 46(6): 642-647.
19. Anon: Lipid-lowering drugs. Med Lett Drugs Ther 1985; 27(695): 74-76.
20. Anon: Chaparral-induced toxic hepatitis - California and Texas, 1992. MMWR 1992; 41(43):812-814.
21. Anderson PC & McLean AEM: Comfrey and liver damage. Hum Toxicol 1989; 8:68-69.
22. Larrey D, Vial T, Pauwels A et al: Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117:129-132.
23. Garg A & Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264(6):723-726.
24.Bennett WM, Aronoff GR, Golper TA et al: Drug prescribing in Renal Failure, 3rd ed. American College of Physicians, Philadelphia, PA, 1994.
25. Huxtable RJ: The myth of beneficent nature: the risks of herbal preparations Ann Intern Med 1992; 117:165-166.
26. Smith LW & Culvenor CCJ: Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Products 1981; 44(2):129-152.
27. NIACOR(R), niacin (niacinamide). Upsher-Smith Laboratories, Minneapolis, MN, Feb 2000.